دورية أكاديمية
Niraparib for the treatment of ovarian cancer.
| العنوان: | Niraparib for the treatment of ovarian cancer. |
|---|---|
| المؤلفون: | Essel KG; a Division of Gynecologic Oncology , University of Oklahoma Stephenson Cancer Center , Oklahoma City , USA., Moore KN; a Division of Gynecologic Oncology , University of Oklahoma Stephenson Cancer Center , Oklahoma City , USA. |
| المصدر: | Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2018 Aug; Vol. 18 (8), pp. 727-733. Date of Electronic Publication: 2018 Jul 02. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101123358 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8328 (Electronic) Linking ISSN: 14737140 NLM ISO Abbreviation: Expert Rev Anticancer Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2015- : Abingdon, Oxford : Taylor & Francis Original Publication: London : Future Drugs Ltd., c2001- |
| مواضيع طبية MeSH: | Indazoles/*administration & dosage , Ovarian Neoplasms/*drug therapy , Piperidines/*administration & dosage , Poly(ADP-ribose) Polymerase Inhibitors/*administration & dosage, Biomarkers, Tumor/metabolism ; Dose-Response Relationship, Drug ; Female ; Humans ; Indazoles/adverse effects ; Indazoles/pharmacology ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Piperidines/adverse effects ; Piperidines/pharmacology ; Poly(ADP-ribose) Polymerase Inhibitors/adverse effects ; Poly(ADP-ribose) Polymerase Inhibitors/pharmacology ; Practice Guidelines as Topic |
| مستخلص: | Introduction: Niraparib, an orally available selective inhibitor of poly(adenosine diphosphate-ribose) polymerase (PARP), is the first PARP inhibitor approved for use in patients with ovarian cancer who do not harbor a germ-line or somatic mutation in the breast cancer gene (BRCA). Overall, niraparib is well tolerated and its toxicities, primarily hematologic, are manageable especially with recently released initial dose modification guidelines based on weight and baseline platelet count. The role of niraparib as maintenance following frontline platinum-based chemotherapy as well as in the treatment of recurrent high-grade serous ovarian cancer is an active area of investigation. Areas covered: This review focuses on niraparib, its pharmacology, clinical efficacy, and adverse effects as evidenced by prospective clinical trials, and licensed indications. Expert commentary: Niraparib introduced the use of PARP inhibitors regardless of biomarker status. Recent studies highlight the critical need for more accurate biomarkers to identify patients most likely to benefit from treatment with PARP inhibitors. In the next 5 years, we anticipate further expansion of and elucidation regarding the optimal indication for use of niraparib in the treatment of ovarian cancer. |
| فهرسة مساهمة: | Keywords: BRCA; Niraparib; PARP inhibitor; homologous recombination deficiency; ovarian cancer |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) 0 (Indazoles) 0 (Piperidines) 0 (Poly(ADP-ribose) Polymerase Inhibitors) HMC2H89N35 (niraparib) |
| تواريخ الأحداث: | Date Created: 20180619 Date Completed: 20190206 Latest Revision: 20190215 |
| رمز التحديث: | 20240829 |
| DOI: | 10.1080/14737140.2018.1490180 |
| PMID: | 29911447 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-8328 |
|---|---|
| DOI: | 10.1080/14737140.2018.1490180 |